Keyphrases
5-HT1A Receptor
7%
Antipsychotic-free
6%
Antipsychotics
9%
Assessment Scale
5%
At-risk Mental State
47%
Atypical Antipsychotics
7%
Brain Regions
5%
Brief Assessment of Cognition in Schizophrenia
9%
Chronic Schizophrenia
8%
Clinical Characteristics
5%
Clinical High Risk for Psychosis (CHR-P)
21%
Cognitive Function
23%
Cognitive Impairment
13%
Control Subjects
6%
Current Density
6%
Current Source Density
6%
Duration Mismatch
14%
Event-related Potentials
9%
Fatty Acid Composition
5%
First-episode Psychosis
15%
Functional Outcome
8%
Functioning Assessment
5%
Healthy Controls
15%
High-risk Subjects
7%
Illness
5%
Individuals at Risk
13%
Japanese Version
7%
Low-resolution Electromagnetic Tomography
6%
Mismatch Negativity
18%
Negative Symptoms
9%
Occupational Functioning
5%
Olanzapine
8%
Olfactory Function
5%
P300
13%
Patients with Schizophrenia
41%
Positive Symptoms
8%
Psychosis
25%
Quality of Life
7%
Rating Scales
13%
Schizophrenia
100%
Schizophrenic Patients
16%
Serotonin-1A Receptor
6%
SLORETA
11%
Social Cognition
6%
Social Function
8%
Social Functioning
6%
Socio-cognitive
11%
Tomographic Analysis
6%
Verbal Memory
5%
Vulnerability
6%
Neuroscience
5-HT Receptor
5%
5-HT1A Receptor
10%
Antipsychotic
11%
Atypical Antipsychotic
7%
Cognitive Disorders
23%
Cognitive Function
32%
Electromagnetism
20%
Erythrocyte Membrane
5%
Event-Related Potential
17%
Fatty Acids
7%
Gyri
7%
Longitudinal Study
6%
Magnetic Resonance Imaging
11%
Mismatch Negativity
21%
Negative Syndrome
21%
Neuropsychological Assessment
5%
Olanzapine
8%
Pineal Gland
6%
Polyunsaturated Fatty Acid
9%
Positive Syndrome
17%
Psychosis
7%
Schizophrenia
9%
Social Cognition
9%
Superior Temporal Gyrus
6%
Typical Antipsychotic
22%
Working Memory
5%
